Xellia Pharms Aps patents expiration
1. Daptomycin patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11759497 | XELLIA PHARMS APS | Daptomycin formulations |
Aug, 2038
(14 years from now) | |
Drugs and Companies using DAPTOMYCIN ingredient
Market Authorisation Date: 30 January, 2023
Treatment: NA
Dosage: POWDER;INTRAVENOUS
More Information on Dosage
DAPTOMYCIN family patents
2. Vancomycin patents expiration
VANCOMYCIN's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11517609 | XELLIA PHARMS APS | Glycopeptide compositions |
Nov, 2035
(11 years from now) | |
| US10039804 | XELLIA PHARMS APS | Glycopeptide compositions |
Nov, 2035
(11 years from now) | |
| US10849956 | XELLIA PHARMS APS | Glycopeptide compositions |
Nov, 2035
(11 years from now) | |
| US11000567 | XELLIA PHARMS APS | Glycopeptide compositions |
Nov, 2035
(11 years from now) | |
| US10188697 | XELLIA PHARMS APS | Glycopeptide compositions |
Nov, 2035
(11 years from now) | |
Drugs and Companies using VANCOMYCIN ingredient
Market Authorisation Date: 26 August, 2021
Treatment: Method of treating bacterial infections
Dosage: SOLUTION;INTRAVENOUS, ORAL
More Information on Dosage
VANCOMYCIN family patents
3. Vancomycin Hydrochloride patents expiration
VANCOMYCIN HYDROCHLORIDE's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11628200 | XELLIA PHARMS APS | Glycopeptide compositions |
Nov, 2035
(11 years from now) | |
| US10188697 | XELLIA PHARMS APS | Glycopeptide compositions |
Nov, 2035
(11 years from now) | |
| US10039804 | XELLIA PHARMS APS | Glycopeptide compositions |
Nov, 2035
(11 years from now) | |
| US10849956 | XELLIA PHARMS APS | Glycopeptide compositions |
Nov, 2035
(11 years from now) | |
| US11517609 | XELLIA PHARMS APS | Glycopeptide compositions |
Nov, 2035
(11 years from now) | |
Drugs and Companies using VANCOMYCIN HYDROCHLORIDE ingredient
Market Authorisation Date: 15 February, 2019
Treatment: Method of treating bacterial infections
Dosage: SOLUTION;INTRAVENOUS
More Information on Dosage
VANCOMYCIN HYDROCHLORIDE family patents